New research suggests that patients who discontinue blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who end traditional diet and exercise plans.
Research printed in a leading health publication shows that while obese people often shed substantial amounts of their total mass while on the medication, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"People buying these treatments should be cognizant of the risk of quick rebound weight gain when the therapy is stopped," warns expert Dr. Susan Jebb.
That rate of recovery implies a reversion to original weight within about one and a half years.
Weighing Treatments
The research, which examined 37 of studies involving over 9,000 of participants, compared the effects of these new drugs with older methods.
Scientists note that individuals who shed pounds through lifestyle changes alone generally have a slower weight regain—approximately 0.1 kg a month—once they finish.
Understanding the Fast Regain
Experts believe the way of the drugs explains the heightened weight return.
GLP-1 drugs mimic a natural hormone called GLP-1, which moderates hunger.
"Long-term administration of the hormone concentrations several times higher than the body's typical production could lead to the body to generate a reduced amount of its endogenous hormone, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication results in hunger is uncontrolled, making binge eating a significant risk."
A Lifelong Disease?
Medical guidelines suggest the jabs for people with weight-linked health risks, alongside prescribed lifestyle changes.
Professionals say that, considering the likelihood of relapse, the treatment is often long-term.
This opinion is reinforced by pharmaceutical companies, who say that the findings "emphasize the long-term character of obesity," comparing it to managing diseases like high blood pressure.
User Testimonies
Individuals who have discontinued the jabs report a intense return of cravings.
"It was like a switch that goes on and you become ravenous," recalled one woman.
The struggle is exacerbated if users have not established sustainable dietary or behavioural modifications during treatment.
Growing Use
Survey data show that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.
- Use is more common among women compared to males.
- The middle-aged demographic shows the highest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
Finally, researchers caution that while these medications are potent tools for shedding pounds, they are not a permanent cure and lasting health benefits hinges on combined behavioural support.
